Donald Yergeau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Donald Yergeau has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Heather L. Mulder
St. Jude Children’s Research Hospital 2 Department of Computational Biology Memphis, Tennessee
9 shared publications - Jinghui Zhang
St Jude Children's Research Hospital, Memphis, TN
9 shared publications C. Michel Zwaan
7 shared publications- Dirk Reinhardt
23Gesellschaft für Pädiatrische Onkologie und Hämatologie, Essen, Germany
7 shared publications - Esther A. Obeng
St. Jude Children’s Research Hospital
7 shared publications - Franco Locatelli
Department of Pediatric Hematology/Oncology, Cell and Gene Therapy IRCCS Bambino Gesù Children's Hospital Rome Italy
7 shared publications
Latest Publications
- Open Access
High-Intensity Interval Exercise Drives Vitamin D Receptor Expression in Skeletal Muscle via Recruitment of Non-Parenchymal Cells, Not Upregulation in Muscle Fibers
Background: High-intensity interval exercise (HIIE) is gaining interest as an alternative to traditional moderate-intensity exercise due to its shorter exercise regimens. Yet, it still induces significant muscular adaptations, including metabolic remodeling, enhanced mitochondrial biogenesis, and improved endurance capacity. Exercise has been shown to increase vitamin D receptor (VDR) expression acutely; however, the role of this effect and whether it occurs during HIIE remain to be elucidated. Objectives/Methods: Here, we investigated the time-dependent effects of a single bout of high-intensity interval exercise (HIIE) on systemic inflammatory cytokine profiles and gene expression, including VDR, in aged skeletal muscle. Sedentary aged mice (male C57Bl/6J at 24 months of age) were provided a 10-min HIIE session, and blood and tissues were harvested at 1-, 4-, and 24-h post-exercise, and compared with sedentary mice. Results: Our findings indicate that HIIE elicits a transient systemic inflammatory response peaking at 4 h post-exercise and returning to pre-exercise levels by 24 h. Using principal component analysis, we identified a similar pattern in the mRNA profiles, with clear clusters separating sedentary groups at 1 and 4 h after acute HIIE, but not after 24 h. Although VDR mRNA follows this pattern, protein expression, as determined by Western blot and immunohistochemical analysis, reveals persistence at 24 h. As VDR was localized to the periphery of muscle fibers, we investigated and found that VDR co-localizes with PAX7 (a marker for satellite cells) and F4/80-expressing macrophages. This suggests that the observed increase in VDR expression following exercise may be attributed to ancillary cell response during muscle remodeling. Conclusions: Together, these results provide novel insights into the transient molecular changes occurring 1 and 4 h after HIIE, which subsequently return to baseline after 24 h. This highlights the potential of HIIE in muscle adaptation and recovery, particularly in older individuals.
Open AccessHigh-Intensity Interval Exercise Drives Vitamin D Receptor Expression in Skeletal Muscle via Recruitment of Non-Parenchymal Cells, Not Upregulation in Muscle Fibers
Background: High-intensity interval exercise (HIIE) is gaining interest as an alternative to traditional moderate-intensity exercise due to its shorter exercise regimens. Yet, it still induces significant muscular adaptations, including metabolic remodeling, enhanced mitochondrial biogenesis, and improved endurance capacity. Exercise has been shown to increase vitamin D receptor (VDR) expression acutely; however, the role of this effect and whether it occurs during HIIE remain to be elucidated. Objectives/Methods: Here, we investigated the time-dependent effects of a single bout of high-intensity interval exercise (HIIE) on systemic inflammatory cytokine profiles and gene expression, including VDR, in aged skeletal muscle. Sedentary aged mice (male C57Bl/6J at 24 months of age) were provided a 10-min HIIE session, and blood and tissues were harvested at 1-, 4-, and 24-h post-exercise, and compared with sedentary mice. Results: Our findings indicate that HIIE elicits a transient systemic inflammatory response peaking at 4 h post-exercise and returning to pre-exercise levels by 24 h. Using principal component analysis, we identified a similar pattern in the mRNA profiles, with clear clusters separating sedentary groups at 1 and 4 h after acute HIIE, but not after 24 h. Although VDR mRNA follows this pattern, protein expression, as determined by Western blot and immunohistochemical analysis, reveals persistence at 24 h. As VDR was localized to the periphery of muscle fibers, we investigated and found that VDR co-localizes with PAX7 (a marker for satellite cells) and F4/80-expressing macrophages. This suggests that the observed increase in VDR expression following exercise may be attributed to ancillary cell response during muscle remodeling. Conclusions: Together, these results provide novel insights into the transient molecular changes occurring 1 and 4 h after HIIE, which subsequently return to baseline after 24 h. This highlights the potential of HIIE in muscle adaptation and recovery, particularly in older individuals.
- Open Access
- 11 July 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (29)
Life stage–specific poly(A) site selection regulated byTrypanosoma bruceiDRBD18
The kinetoplastid parasite,Trypanosoma brucei, undergoes a complex life cycle entailing slender and stumpy bloodstream forms in mammals and procyclic and metacyclic forms (MFs) in tsetse fly hosts. The numerous gene regulatory events that underlieT. bruceidifferentiation between hosts, as well as between active and quiescent stages within each host, take place in the near absence of transcriptional control. Rather, differentiation is controlled by RNA-binding proteins (RBPs) that associate with mRNA 3′ untranslated regions (3′UTRs) to impact RNA stability and translational efficiency. DRBD18 is a multifunctionalT. bruceiRBP, shown to impact mRNA stability, translation, export, and processing. Here, we use single-cell RNAseq to characterize transcriptomic changes in cell populations that arise upon DRBD18 depletion, as well as to visualize transcriptome-wide alterations to 3′UTR length. We show that in procyclic insect stages, DRBD18 represses expression of stumpy bloodstream form and MF transcripts. Additionally, DRBD18 regulates the 3′UTR lengths of over 1,500 transcripts, typically promoting the use of distal polyadenylation sites, and thus the inclusion of 3′UTR regulatory elements. Remarkably, comparison of polyadenylation patterns in DRBD18 knockdowns with polyadenylation patterns in stumpy bloodstream forms shows numerous similarities, revealing a role for poly(A) site selection in developmental gene regulation, and indicating that DRBD18 controls this process for a set of transcripts. RNA immunoprecipitation supports a direct role for DRBD18 in poly(A) site selection. This report highlights the importance of alternative polyadenylation inT. bruceidevelopmental control and identifies a critical RBP in this process.
- 11 July 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (29)
Open AccessLife stage–specific poly(A) site selection regulated byTrypanosoma bruceiDRBD18
The kinetoplastid parasite,Trypanosoma brucei, undergoes a complex life cycle entailing slender and stumpy bloodstream forms in mammals and procyclic and metacyclic forms (MFs) in tsetse fly hosts. The numerous gene regulatory events that underlieT. bruceidifferentiation between hosts, as well as between active and quiescent stages within each host, take place in the near absence of transcriptional control. Rather, differentiation is controlled by RNA-binding proteins (RBPs) that associate with mRNA 3′ untranslated regions (3′UTRs) to impact RNA stability and translational efficiency. DRBD18 is a multifunctionalT. bruceiRBP, shown to impact mRNA stability, translation, export, and processing. Here, we use single-cell RNAseq to characterize transcriptomic changes in cell populations that arise upon DRBD18 depletion, as well as to visualize transcriptome-wide alterations to 3′UTR length. We show that in procyclic insect stages, DRBD18 represses expression of stumpy bloodstream form and MF transcripts. Additionally, DRBD18 regulates the 3′UTR lengths of over 1,500 transcripts, typically promoting the use of distal polyadenylation sites, and thus the inclusion of 3′UTR regulatory elements. Remarkably, comparison of polyadenylation patterns in DRBD18 knockdowns with polyadenylation patterns in stumpy bloodstream forms shows numerous similarities, revealing a role for poly(A) site selection in developmental gene regulation, and indicating that DRBD18 controls this process for a set of transcripts. RNA immunoprecipitation supports a direct role for DRBD18 in poly(A) site selection. This report highlights the importance of alternative polyadenylation inT. bruceidevelopmental control and identifies a critical RBP in this process.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables and Figures from Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators
Supplementary Tables and Figures
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables and Figures from Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators
Supplementary Tables and Figures
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables and Figures from Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators
Supplementary Tables and Figures
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables and Figures from Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators
Supplementary Tables and Figures
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators
Genomic characterization of pediatric patients with acute myeloid leukemia (AML) has led to the discovery of somatic mutations with prognostic implications. Although gene-expression profiling can differentiate subsets of pediatric AML, its clinical utility in risk stratification remains limited. Here, we evaluate gene expression, pathogenic somatic mutations, and outcome in a cohort of 435 pediatric patients with a spectrum of pediatric myeloid-related acute leukemias for biological subtype discovery. This analysis revealed 63 patients with varying immunophenotypes that span a T-lineage and myeloid continuum designated as acute myeloid/T-lymphoblastic leukemia (AMTL). Within AMTL, two patient subgroups distinguished by FLT3-ITD and PRC2 mutations have different outcomes, demonstrating the impact of mutational composition on survival. Across the cohort, variability in outcomes of patients within isomutational subsets is influenced by transcriptional identity and the presence of a stem cell–like gene-expression signature. Integration of gene expression and somatic mutations leads to improved risk stratification.Significance:Immunophenotype and somatic mutations play a significant role in treatment approach and risk stratification of acute leukemia. We conducted an integrated genomic analysis of pediatric myeloid malignancies and found that a combination of genetic and transcriptional readouts was superior to immunophenotype and genomic mutations in identifying biological subtypes and predicting outcomes.This article is highlighted in the In This Issue feature, p. 549
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators
Genomic characterization of pediatric patients with acute myeloid leukemia (AML) has led to the discovery of somatic mutations with prognostic implications. Although gene-expression profiling can differentiate subsets of pediatric AML, its clinical utility in risk stratification remains limited. Here, we evaluate gene expression, pathogenic somatic mutations, and outcome in a cohort of 435 pediatric patients with a spectrum of pediatric myeloid-related acute leukemias for biological subtype discovery. This analysis revealed 63 patients with varying immunophenotypes that span a T-lineage and myeloid continuum designated as acute myeloid/T-lymphoblastic leukemia (AMTL). Within AMTL, two patient subgroups distinguished by FLT3-ITD and PRC2 mutations have different outcomes, demonstrating the impact of mutational composition on survival. Across the cohort, variability in outcomes of patients within isomutational subsets is influenced by transcriptional identity and the presence of a stem cell–like gene-expression signature. Integration of gene expression and somatic mutations leads to improved risk stratification.Significance:Immunophenotype and somatic mutations play a significant role in treatment approach and risk stratification of acute leukemia. We conducted an integrated genomic analysis of pediatric myeloid malignancies and found that a combination of genetic and transcriptional readouts was superior to immunophenotype and genomic mutations in identifying biological subtypes and predicting outcomes.This article is highlighted in the In This Issue feature, p. 549
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators
Genomic characterization of pediatric patients with acute myeloid leukemia (AML) has led to the discovery of somatic mutations with prognostic implications. Although gene-expression profiling can differentiate subsets of pediatric AML, its clinical utility in risk stratification remains limited. Here, we evaluate gene expression, pathogenic somatic mutations, and outcome in a cohort of 435 pediatric patients with a spectrum of pediatric myeloid-related acute leukemias for biological subtype discovery. This analysis revealed 63 patients with varying immunophenotypes that span a T-lineage and myeloid continuum designated as acute myeloid/T-lymphoblastic leukemia (AMTL). Within AMTL, two patient subgroups distinguished by FLT3-ITD and PRC2 mutations have different outcomes, demonstrating the impact of mutational composition on survival. Across the cohort, variability in outcomes of patients within isomutational subsets is influenced by transcriptional identity and the presence of a stem cell–like gene-expression signature. Integration of gene expression and somatic mutations leads to improved risk stratification.Significance:Immunophenotype and somatic mutations play a significant role in treatment approach and risk stratification of acute leukemia. We conducted an integrated genomic analysis of pediatric myeloid malignancies and found that a combination of genetic and transcriptional readouts was superior to immunophenotype and genomic mutations in identifying biological subtypes and predicting outcomes.This article is highlighted in the In This Issue feature, p. 549
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators
Genomic characterization of pediatric patients with acute myeloid leukemia (AML) has led to the discovery of somatic mutations with prognostic implications. Although gene-expression profiling can differentiate subsets of pediatric AML, its clinical utility in risk stratification remains limited. Here, we evaluate gene expression, pathogenic somatic mutations, and outcome in a cohort of 435 pediatric patients with a spectrum of pediatric myeloid-related acute leukemias for biological subtype discovery. This analysis revealed 63 patients with varying immunophenotypes that span a T-lineage and myeloid continuum designated as acute myeloid/T-lymphoblastic leukemia (AMTL). Within AMTL, two patient subgroups distinguished by FLT3-ITD and PRC2 mutations have different outcomes, demonstrating the impact of mutational composition on survival. Across the cohort, variability in outcomes of patients within isomutational subsets is influenced by transcriptional identity and the presence of a stem cell–like gene-expression signature. Integration of gene expression and somatic mutations leads to improved risk stratification.Significance:Immunophenotype and somatic mutations play a significant role in treatment approach and risk stratification of acute leukemia. We conducted an integrated genomic analysis of pediatric myeloid malignancies and found that a combination of genetic and transcriptional readouts was superior to immunophenotype and genomic mutations in identifying biological subtypes and predicting outcomes.This article is highlighted in the In This Issue feature, p. 549
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S11 from The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment
Supplementary Figures S1-S11 show sample histology, quality control data, and additional genomic analysis. S1. Histology of osteosarcoma SJOS001101. S2. Whole-genome sequencing coverage metrics. S3. Deep capture validation coverage metrics. S4. Example genes experiencing copy number alterations. S5. B-allele frequencies confirm homozygous deletions of 3q13.31 and CDKN2A. S6. Identification of cisplatin mutation signature in osteosarcoma. S7. Cisplatin does not induce kataegis. S8. Density plot analysis of SNV clusters reveals unique clones at most sites. S9. SJOS001101 pairwise osteosarcoma sample SNV comparisons reveal cross-seeding. S10. Clonal evolution of SJOS001101 as clarified by MACHINA analysis. S11. Pairwise osteosarcoma sample SNV comparisons in three additional patients.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S11 from The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment
Supplementary Figures S1-S11 show sample histology, quality control data, and additional genomic analysis. S1. Histology of osteosarcoma SJOS001101. S2. Whole-genome sequencing coverage metrics. S3. Deep capture validation coverage metrics. S4. Example genes experiencing copy number alterations. S5. B-allele frequencies confirm homozygous deletions of 3q13.31 and CDKN2A. S6. Identification of cisplatin mutation signature in osteosarcoma. S7. Cisplatin does not induce kataegis. S8. Density plot analysis of SNV clusters reveals unique clones at most sites. S9. SJOS001101 pairwise osteosarcoma sample SNV comparisons reveal cross-seeding. S10. Clonal evolution of SJOS001101 as clarified by MACHINA analysis. S11. Pairwise osteosarcoma sample SNV comparisons in three additional patients.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S5 from The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment
Osteosarcoma clinical history and capture validation sequencing data. Supplementary Table S1. Sample and treatment information for relapsed osteosarcoma patients. Supplementary Table S2. SJOS0011101 SNVs detected by capture validation and tumor purity. Supplementary Table S3. SJOS0011105 SNVs detected by capture validation and tumor purity. Supplementary Table S4. SJOS0011107 SNVs detected by capture validation and tumor purity. Supplementary Table S5. SJOS010 SNVs detected by capture validation and tumor purity.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S5 from The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment
Osteosarcoma clinical history and capture validation sequencing data. Supplementary Table S1. Sample and treatment information for relapsed osteosarcoma patients. Supplementary Table S2. SJOS0011101 SNVs detected by capture validation and tumor purity. Supplementary Table S3. SJOS0011105 SNVs detected by capture validation and tumor purity. Supplementary Table S4. SJOS0011107 SNVs detected by capture validation and tumor purity. Supplementary Table S5. SJOS010 SNVs detected by capture validation and tumor purity.